Literature DB >> 17016429

Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage.

S Nandi1, L S Reinert, A Hachem, K Mazan-Mamczarz, P Hagner, H He, R B Gartenhaus.   

Abstract

We discovered a novel oncogene in a T-cell lymphoma cell line, multiple copies in T-cell lymphoma-1 (MCT-1), that has been shown to decrease cell-doubling time, shorten the duration of G(1) transit time and/or G(1)-S transition, and transform NIH3T3 fibroblasts. We subsequently demonstrated that there were significantly increased levels of MCT-1 protein in a subset of primary diffuse large B-cell lymphomas. Levels of MCT-1 protein were shown to be increased after exposure to DNA damaging agents. This increase did not require new protein synthesis, suggesting that post-translational mechanisms were involved. Phosphorylation is one potential mechanism by which the activity of molecules involved in cell cycle/survival is rapidly modulated. The RAS/mitogen-activated/extracellular-regulated kinase (MEK)/extracellular signal-regulated kinases (ERK) pathway plays a prominent role in the regulation of cell growth and proliferation through phosphorylation-dependent regulation of several substrates. The MCT-1 protein is predicted to have numerous putative phosphorylation sites. Using a combination of genetic and pharmacological approaches, we established that phosphorylation of MCT-1 protein by p44/p42 mitogen-activated protein kinases is critical for stabilization of MCT-1 protein and for its ability to promote cell proliferation. Our data suggests that targeting the RAS/MEK/ERK signal transduction cascade may provide a potential therapeutic approach in lymphomas and related malignancies that exhibit high levels of MCT-1 protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016429     DOI: 10.1038/sj.onc.1210030

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Expression and purification of recombinant human MCT-1 oncogene in insect cells.

Authors:  Isabel Pérez-Arellano; Roberto Gozalbo-Rovira; Ana Isabel Martínez; Javier Cervera
Journal:  Protein J       Date:  2010-02       Impact factor: 2.371

2.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Authors:  Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

Review 3.  Novel disease targets and management approaches for diffuse large B-cell lymphoma.

Authors:  Wyndham H Wilson; Francisco J Hernandez-Ilizaliturri; Kieron Dunleavy; Richard F Little; Owen A O'Connor
Journal:  Leuk Lymphoma       Date:  2010-08

4.  Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.

Authors:  Bojie Dai; X Frank Zhao; Patrick Hagner; Paul Shapiro; Krystyna Mazan-Mamczarz; Shuchun Zhao; Yasodha Natkunam; Ronald B Gartenhaus
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

Review 5.  Targeting the translational machinery as a novel treatment strategy for hematologic malignancies.

Authors:  Patrick R Hagner; Abraham Schneider; Ronald B Gartenhaus
Journal:  Blood       Date:  2010-01-14       Impact factor: 22.113

6.  DENR-MCT-1 promotes translation re-initiation downstream of uORFs to control tissue growth.

Authors:  Katrin Strassburger; Philipp Christoph Janiesch; Sibylle Schleich; Tatyana Koledachkina; Katharine K Miller; Katharina Haneke; Yong-Sheng Cheng; Katrin Kuechler; Georg Stoecklin; Kent E Duncan; Aurelio A Teleman
Journal:  Nature       Date:  2014-07-06       Impact factor: 49.962

7.  Crystal Structure of the Human Ribosome in Complex with DENR-MCT-1.

Authors:  Ivan B Lomakin; Elena A Stolboushkina; Anand T Vaidya; Chenguang Zhao; Maria B Garber; Sergey E Dmitriev; Thomas A Steitz
Journal:  Cell Rep       Date:  2017-07-18       Impact factor: 9.423

8.  MCTS1 promotes invasion and metastasis of oral cancer by modifying the EMT process.

Authors:  Zhexun Huang; Qiao Su; Wuguo Li; Hui Ren; Huiqiang Huang; Anxun Wang
Journal:  Ann Transl Med       Date:  2021-06

9.  The oncogene mcts1.

Authors:  Ali Hachem; Suvobroto Nandi
Journal:  Transl Oncogenomics       Date:  2007-07-19

10.  Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity.

Authors:  Hung-Ju Shih; Hsiao-Huei Chen; Yen-An Chen; Meng-Hsun Wu; Gan-Guang Liou; Wei-Wen Chang; Linyi Chen; Lu-Hai Wang; Hsin-Ling Hsu
Journal:  Oncotarget       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.